Publicação
Genomic-based coverage prediction for MenB vaccines on Portuguese invasive Neisseria meningitidis strains
| dc.contributor.author | Bettencourt, Célia | |
| dc.contributor.author | Simões, Maria João | |
| dc.date.accessioned | 2022-11-15T12:53:16Z | |
| dc.date.available | 2022-11-15T12:53:16Z | |
| dc.date.issued | 2022-04-25 | |
| dc.description.abstract | Neisseria meningitidis is a commensal bacteria of the human nasopharynx that occasionally cause serious invasive infections including fatal sepsis and meningitis. Meningococci are classified into 12 serogroups based on structural differences in capsular polysaccharide, but only six serogroups (A, B, C, W, Y, and more recently X) are the most frequent causes of invasive meningococcal disease (IMD) worldwide. Portugal registered 1359 of IMD confirmed cases between 2003 and 2019, with MenB harboring 71% of all confirmed cases, followed by serogroup C with only 9.7%. Cases due to serogroup Y (MenY) accounted for 5.1%, while serogroup W showed a marked increase in cases over the last four years, ranging from 1.4% in 2012 to 15.5 % in 2019. To prevent IMD caused by MenB two vaccines are available: the 4CMenB included in the Portuguese routine immunization programme in October 2020 and recommended for children above two months of age, and the bivalent rLP2086 licensed in 2017 for individuals older than 10 years old. Moreover, these vaccines have been shown to have potential in several meningococcal serogroups other than serogroup B. The multicomponent vaccine 4CMenB includes two fusion proteins, namely the Neisserial Heparin Binding Antigen-GNA1030 (NHBA, peptide 2) and the factor H binding protein-GNA2091 (fHbp, peptide 1, subfamily B), and the single antigen Neisserial adhesin A (NadA, peptide 8), combined with the outer membrane vesicles (OMV) the PorA peptide 4 of the variable region 2 (P1.4). Regarding the bivalent rLP2086 vaccine, it contains two subfamilies of the fHbp namely the subfamily A (peptide 45) and subfamily B (peptide 55) classified based on their genetic variation. The aim of this study was to predict the coverage of the 4CMenB and rLP2086 vaccines against Portuguese Neisseria meningitidis isolates collected between 2012 and 2019 and to provide an analysis on the diversity of the vaccine antigens based on genomic analysis. | pt_PT |
| dc.description.version | N/A | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.18/8314 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Neisseria meningitidis | pt_PT |
| dc.subject | MenB Vaccines | pt_PT |
| dc.subject | Strain Coverage | pt_PT |
| dc.subject | Infecções Respiratórias | pt_PT |
| dc.subject | Portugal | pt_PT |
| dc.title | Genomic-based coverage prediction for MenB vaccines on Portuguese invasive Neisseria meningitidis strains | pt_PT |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Lisboa, Portugal (online) | pt_PT |
| oaire.citation.title | 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 23-26 April 2022 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | conferenceObject | pt_PT |
Ficheiros
Principais
1 - 1 de 1
A carregar...
- Nome:
- Poster_ECCMID_2022.pdf
- Tamanho:
- 1.02 MB
- Formato:
- Adobe Portable Document Format